FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa
Executive Summary
In an unusual essay in the New England Journal of Medicine, CDER Director Janet Woodcock acknowledges that “the conservative approach did not provide the right conclusion regarding therapeutic equivalence in a timely manner.”
You may also be interested in...
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
FDA’s New ‘Super Office’ Attacks Pharmaceutical Quality Risks
Launched this month, CDER’s OPQ ‘Super Office’ blends the agency’s CMC review programs for new and generic drugs together, and focuses them on significant risks like the difficulty of release-testing modified-release drugs.